Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × telotristat ethyl × NET × Clear all

Status

Sponsor Class

OTHER 3 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

NET 1 Gastrointestinal 1 Endocrine 1

Conditions

Serotonin Syndrome 1 Neuroendocrine Tumors 1

Interventions

Everolimus 15 lutetium Lu 177 dotatate 8 surufatinib 7 lanreotide 6 Sunitinib 5 Octreotide 5 amino-acid, glucose, and electrolyte solution 4 Temozolomide 4 Data Collection 4 pembrolizumab 3 pasireotide 3 177Lu-octreotide, DOTA(0)-Tyr(3)- 3 tislelizumab 2 fosbretabulin 2 arginyllysine 2 PM 01183 2 Irinotecan 2 Injections 2 64Cu-SARTATE 2 3-Iodobenzylguanidine 2 toripalimab 1 telotristat ethyl 1 taxane 1 repotrectinib 1 pralsetinib 1 liposomal doxorubicin 1 gadoteridol 1 gadoterate meglumine 1 gadolinium ethoxybenzyl DTPA 1 gadodiamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03223428 2024-07-24

RELAX

TerSera Therapeutics LLC

223 enrolled 16 charts

Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡